<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35603503</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1475-6374</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>37</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of enzyme inhibition and medicinal chemistry</Title>
          <ISOAbbreviation>J Enzyme Inhib Med Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>From Antarctica to cancer research: a novel human DNA topoisomerase 1B inhibitor from Antarctic sponge <i>Dendrilla antarctica</i>.</ArticleTitle>
        <Pagination>
          <StartPage>1404</StartPage>
          <EndPage>1410</EndPage>
          <MedlinePgn>1404-1410</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/14756366.2022.2078320</ELocationID>
        <Abstract>
          <AbstractText>Nature has been always a great source of possible lead compounds to develop new drugs against several diseases. Here we report the identification of a natural compound, membranoid G, derived from the Antarctic sponge <i>Dendrilla antarctica</i> displaying an <i>inÂ vitro</i> inhibitory activity against human DNA topoisomerase 1B. The experiments indicate that membranoid G, when pre-incubated with the enzyme, strongly and irreversibly inhibits the relaxation of supercoiled DNA. This compound completely inhibits the cleavage step of the enzyme catalytic mechanism by preventing protein binding to the DNA. Membranoid G displays also a cytotoxic effect on tumour cell lines, suggesting its use as a possible lead compound to develop new anticancer drugs.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ottaviani</LastName>
            <ForeName>Alessio</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biology, University of Rome Tor Vergata, Rome, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Welsch</LastName>
            <ForeName>Joshua</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, University of South Florida, Tampa, FL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Agama</LastName>
            <ForeName>Keli</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pommier</LastName>
            <ForeName>Yves</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Desideri</LastName>
            <ForeName>Alessandro</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0003-1541-4217</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biology, University of Rome Tor Vergata, Rome, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baker</LastName>
            <ForeName>Bill J</ForeName>
            <Initials>BJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, University of South Florida, Tampa, FL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fiorani</LastName>
            <ForeName>Paola</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biology, University of Rome Tor Vergata, Rome, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Translational Pharmacology, National Research Council, CNR, Rome, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Enzyme Inhib Med Chem</MedlineTA>
        <NlmUniqueID>101150203</NlmUniqueID>
        <ISSNLinking>1475-6366</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D059003">Topoisomerase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-49-2</RegistryNumber>
          <NameOfSubstance UI="D004247">DNA</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 5.99.1.2</RegistryNumber>
          <NameOfSubstance UI="D004264">DNA Topoisomerases, Type I</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 5.99.1.3</RegistryNumber>
          <NameOfSubstance UI="D004250">DNA Topoisomerases, Type II</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000864" MajorTopicYN="N" Type="Geographic">Antarctic Regions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="Y">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004264" MajorTopicYN="N">DNA Topoisomerases, Type I</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004250" MajorTopicYN="N">DNA Topoisomerases, Type II</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059003" MajorTopicYN="N">Topoisomerase Inhibitors</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Natural product</Keyword>
        <Keyword MajorTopicYN="N">cancer</Keyword>
        <Keyword MajorTopicYN="N">drug development</Keyword>
        <Keyword MajorTopicYN="N">topoisomerase</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>23</Day>
          <Hour>5</Hour>
          <Minute>15</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35603503</ArticleId>
        <ArticleId IdType="doi">10.1080/14756366.2022.2078320</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
